Doximity, Inc. (NYSE:DOCS – Get Free Report) insider Siddharth Sitaram sold 2,444 shares of Doximity stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $20.41, for a total transaction of $49,882.04. Following the sale, the insider owned 90,706 shares in the company, valued at approximately $1,851,309.46. This represents a 2.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Siddharth Sitaram also recently made the following trade(s):
- On Monday, May 11th, Siddharth Sitaram sold 2,309 shares of Doximity stock. The shares were sold at an average price of $25.77, for a total transaction of $59,502.93.
- On Friday, April 10th, Siddharth Sitaram sold 2,427 shares of Doximity stock. The shares were sold at an average price of $21.09, for a total transaction of $51,185.43.
Doximity Trading Down 1.2%
Shares of NYSE DOCS opened at $20.00 on Friday. Doximity, Inc. has a fifty-two week low of $17.15 and a fifty-two week high of $76.51. The company’s 50-day moving average is $22.36. The company has a market capitalization of $3.66 billion, a PE ratio of 20.21, a P/E/G ratio of 3.44 and a beta of 1.30.
Analysts Set New Price Targets
View Our Latest Research Report on Doximity
Institutional Investors Weigh In On Doximity
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Doximity by 4.1% in the fourth quarter. Vanguard Group Inc. now owns 13,285,485 shares of the company’s stock worth $588,281,000 after acquiring an additional 518,916 shares in the last quarter. William Blair Investment Management LLC raised its position in Doximity by 11.7% in the third quarter. William Blair Investment Management LLC now owns 5,829,169 shares of the company’s stock worth $426,404,000 after acquiring an additional 609,775 shares in the last quarter. Capital World Investors raised its position in Doximity by 5.1% in the fourth quarter. Capital World Investors now owns 5,654,875 shares of the company’s stock worth $250,398,000 after acquiring an additional 273,444 shares in the last quarter. Franklin Resources Inc. raised its position in Doximity by 6.2% in the third quarter. Franklin Resources Inc. now owns 3,357,505 shares of the company’s stock worth $245,601,000 after acquiring an additional 194,912 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in Doximity by 29.4% in the first quarter. Renaissance Technologies LLC now owns 3,059,749 shares of the company’s stock worth $71,292,000 after acquiring an additional 694,300 shares in the last quarter. 87.19% of the stock is currently owned by institutional investors.
About Doximity
Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.
The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.
See Also
- Five stocks we like better than Doximity
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.
